Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Biological age & clocks
Research brief

Weighted Pace of Aging derived in older Swedish twins

The abstract describes a weighted Pace of Aging (wPoA) built from up to nine waves of biomarker data in older Swedish twins, with weights based on time to death; it correlated modestly with established biological age predictors. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The abstract says the original Dunedin Pace of Aging weights all biomarkers equally and came from a young cohort with limited mortality follow-up. [1]

  2. The weighted Pace of Aging was built from up to nine waves of biomarker data in older Swedish twins, with weights based on time to mortality. [1]

  3. The abstract reports modest correlations with all considered predictors, suggesting each measure captures distinct aspects of biological aging. [1]

The source at a glance

Study type / format
Abstract of a longitudinal cohort modeling study
Population / context
Older adults in the Swedish Adoption/Twin Study of Aging cohort
Summary based on
Study abstract
Original publication
September 1, 2026

Why a weighted Pace of Aging was proposed

The abstract states that quantifying the rate of aging matters for understanding age-related physiological decline and predicting late-life outcomes. The original Dunedin Pace of Aging models longitudinal biomarker changes but weights all biomarkers equally and came from a young cohort with limited mortality follow-up. According to the abstract, this limits its use in older populations and where biomarker relevance is uncertain.

Supporting source [1]

Biomarker slopes weighted by time to death

The abstract reports that the weighted Pace of Aging (wPoA) was developed with data from the Swedish Adoption/Twin Study of Aging, a longitudinal cohort of older adults with up to nine waves of biomarker data over three decades. Using mixed-effects models, the authors estimated individual random intercepts and slopes for 10 biomarkers and weighted these random effects by their association with time to mortality. This mortality-informed weighting is described as what distinguishes wPoA from the original Dunedin measure.

Supporting source [1]

Modest correlations with biological age predictors

The abstract states that wPoA correlated positively with established biological age predictors and more strongly with low-dimensional predictors such as the Functional Aging Index and the Frailty Index. It adds that correlations across all considered predictors were modest, which the authors interpret as each measure capturing distinct aspects of biological aging. The abstract presents wPoA as a foundation for future single-timepoint surrogates usable where rich longitudinal data are lacking.

Supporting source [1]

How to interpret this

This is an abstract only; the full text was not reviewed. Design details, sample size, follow-up and effect sizes beyond those stated are not reported here, and the correlations are associations, not evidence of causation or of lifespan benefit.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
A generalized approach for estimating the Pace of Aging.

Sluiskes MH, Deelen J, Putter H, Hägg S, Rodríguez-Girondo M. · europepmc.org · September 1, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    assigns equal weight to all biomarkers
  2. Finding 2 ↑

    up to nine waves of biomarker data
  3. Finding 3 ↑

    Modest correlations across all considered predictors

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…